Berobenatide
PF-08653944 · PF’3944 · MET-097i · Pfizer
Long-acting injectable GLP-1 agonist testing weekly and monthly schedules.
Selected study results
VESPER-3Placebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −12.3 percentage points · 28 weeks · Phase 2b
Placebo-adjusted weight-loss difference · 28 weeks
Study focus: Weight management without type 2 diabetes
Placebo-adjusted difference, not the total change in the active arm.
Weekly-to-monthly dosing maintained weight reduction through week 28.
Adults with obesity/overweight without diabetes; approximately 54 per arm across five arms · Weekly escalation to 1.2 mg, then 4.8 mg monthly (Arm 3) · N not included in this summary · Efficacy estimand; sponsor topline. Results & methods ↗
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Phase 3 VESPER studies include separate monthly VESPER-OA 1 and weekly VESPER-OA-2 knee-osteoarthritis protocols. Both are recruiting; planned enrollment is not efficacy evidence.
Next: Phase 3 obesity readouts and monthly maintenance results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies5 records
VESPER-4
Weight managementOnce-weekly berobenatide in adults with obesity or overweight without type 2 diabetes.
VESPER-5
Weight management with type 2 diabetesOnce-weekly berobenatide in adults with obesity or overweight and type 2 diabetes.
VESPER-6
Weight management with monthly dosingOnce-monthly berobenatide in adults with obesity or overweight.
VESPER-SWITCH
Weight maintenance / switchingPhase 3 switching study in adults with obesity or overweight; registry recruiting.
VESPER-OA-2
Weight management with knee osteoarthritisC6491023: weekly berobenatide versus placebo for 52 weeks; with or without type 2 diabetes. Planned enrollment 756; actual start October 26, 2026; recruiting. Separate from monthly VESPER-OA 1 (NCT07919678). No registry results posted.
Phase 2 studies3 records
VESPER-1
Weight managementEarlier weekly-dose study and exploratory extension; refer to Pfizer’s Phase 2b report for the protocol context.
VESPER-2
Weight managementWeekly-dose Phase 2b study in adults with obesity or overweight; results and program context reported by Pfizer.
VESPER-3
Monthly dosing / maintenanceEvaluated transition from weekly titration to monthly dosing in adults with obesity or overweight without type 2 diabetes; sponsor topline reported.
Related conditions and outcomes
Phase 3 studies4 records
VESPER-OSA-1
Sleep-apnea outcomesPhase 3 obstructive-sleep-apnea study; registry recruiting.
VESPER-OSA-2
Sleep-apnea outcomesSeparate Phase 3 obstructive-sleep-apnea study; registered, not yet recruiting.
VESPER-SUI
Stress urinary incontinencePlacebo-controlled trial in an estimated 900 adult women with stress urinary incontinence and BMI ≥27 kg/m². Change in stress incontinence episode frequency at week 52 is the primary endpoint. Body-weight change is secondary.
VESPER-OA 1
Knee osteoarthritis · monthly dosingC6491022: monthly subcutaneous berobenatide versus placebo for 52 weeks in adults with BMI ≥27 and symptomatic radiographic knee osteoarthritis; diabetes excluded. Planned enrollment 656; actual start October 26, 2026; first posted November 5. WOMAC pain is the primary endpoint; weight is secondary. No results posted.
